Rx00009 - Alendronate


Name:
Alendronate
Rx ID:
Rx00009
Validation Level:
Phenomic Similarity:
0.557
Reference ID:
DB00630
Primary Indications:
Osteogenesis imperfecta; Gaucher's disease
Orphan Indications:
Osteoporosis; Paget's disease of bone; low bone mineral density; glucocorticoid-induced osteoporosis
Rare Indications:
No annotated rare indications.
Common Indications:
No annotated common indications.
Pathways:
superpathway of purine nucleotide salvage; Influenza A - Homo sapiens (human)
Drug Interactions:
Calcium; Calcium Acetate; Calcium Chloride; Diclofenac; Diflunisal; Etodolac; Fenoprofen; Flurbiprofen; Ibuprofen; Indomethacin; ...
Click to show more...
Food Interactions:
Take 30-60 minutes before breakfast. Take with a full glass of water.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00009
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
Gaucher's disease osteoporosis 153 910 31300 21.674 3.07E-138 9.86e-135

Chemical, Pharmacological and Biological Annotations


ATC Code:
M05BA04
Brands:
Alenotop (Pliva); Alned (Laboratorios Belmac); Arendal (Ivax); Beenos (Gedeon Richter); Berlex (Duncan); Denfos (Biofarma); Densidron (Mepha); Dronat (Farmavita); Durost (Perumed); Fixopan (Grupo Farma); Forosa (Kemofarmacija); Fosagen (Aspen Pharmacare); Fosalen (Teriak); Fosmin (Hospimedikka); Fostolin (Actavis); Fosval (Saval); Huesobone (Farmaceutica Latina); Lendrate (Actavis); Oseolen (Intipharma); Ostemax (Polpharma)
Categories:
Bone Density Conservation Agents; Antihypocalcemic Agents; Antiresorptives; Bisphosphonates
ChEBI ID:
2567
PubChem ID:
2088
SMILE:
NCCCC(O)(P(O)(O)=O)P(O)(O)=O
InChI:
1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
Classification:
Kingdom:
Organic Compounds
Superclass:
Organophosphorus Compounds
Class:
Organic Phosphonic Acids and Derivatives
Subclass:
Organic Phosphonic Acids
Indication:
For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
Pharmacodynamics:
Alendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Page...
Click to show more...
Description:
Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Paget’s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyza...
Click to show more...
Mechanism:
The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (s...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
-
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Ready biodegradable
Rat acute toxicity:
1.6956 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor